Chemocentryx Inc (CCXI) 5.35 $CCXI
Why You Shouldn't Bet Against ChemoCentryx (CCXI) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:59AM CDT
One stock that might be an intriguing choice for investors right now is ChemoCentryx
Nasdaq stocks posting largest percentage decreases
AP - Thu Apr 10, 12:34PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
ChemoCentryx Appoints Anne-Marie S. Duliege, M.D., M.S. to Chief Strategic Development Role and Head of Immuno-Oncology
GlobeNewswire - Thu Mar 27, 7:30AM CDT
ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, announced today that it has appointed Anne-Marie S. Duliege, M.D., M.S., to a newly created position within the Company. Effective immediately, Dr. Duliege will be acting as Executive Vice President, Chief of Strategic Development and Head of Immuno-oncology.
ChemoCentryx (CCXI) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 7:36AM CDT
ChemoCentryx (CCXI) Shares March Higher, Can It Continue?
ChemoCentryx (CCXI) Jumps: Stock Rises 9.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 7:51AM CDT
ChemoCentryx, Inc. was a big mover last session, as its shares rose nearly 10% on the day.
ChemoCentryx Announces Financial Results for the Quarter and Year Ended December 31, 2013
GlobeNewswire - Thu Mar 13, 3:05PM CDT
ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, announced today its financial results for the fourth quarter and year ended December 31, 2013.
ChemoCentryx to Hold Fourth Quarter and Year-End 2013 Financial Results Conference Call on Thursday, March 13, 2014
GlobeNewswire - Mon Mar 03, 7:30AM CST
ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that the Company's fourth quarter and year-end 2013 financial results will be released after market close on Thursday, March 13, 2014. ChemoCentryx executive management will host a conference call beginning at 5:00 p.m. Eastern Time on March 13, 2014, to discuss these results and to answer questions.
ChemoCentryx to Present at the Cowen and Company 34th Annual Health Care Conference
GlobeNewswire - Tue Feb 25, 9:28AM CST
ChemoCentryx, Inc. (Nasdaq:CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the Cowen and Company 34 Annual Health Care Conference on Tuesday, March 4, 2014, at 10:40 a.m. Eastern Time at The Boston Marriott Copley Place hotel in Boston, MA.
5 Stocks Poised for Breakouts
at The Street - Fri Feb 21, 12:53PM CST
These stocks look ready to break out and trade higher from current levels.
5 Under-$10 Biotech Stocks to Watch
at The Street - Fri Jan 10, 6:00AM CST
Keep these biotech stocks on your radar.
Diabetic Nephropathy Global Clinical Trials Review, H2 2013 Available Now for Review
M2 - Thu Jan 09, 4:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/djktj4/diabetic) has announced the addition of the "Diabetic Nephropathy Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Diabetic Nephropathy Global Clinical Trials Review, H2, 2013" provides data on the Diabetic Nephropathy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diabetic Nephropathy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Diabetic Nephropathy. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: -Abbott Laboratories -AbbVie Inc. -Bayer AG -ChemoCentryx, Inc. -Eli Lilly and Company -GenKyoTex S.A. -Holstebro Hospital -IMMD Inc. -Islamic Azad University of Tabriz -Joslin Diabetes Center -Kanazawa Medical University -Novartis AG -Okayama University -Pfizer Inc. -Shanghai Jiao Tong University -Shiraz University of Medical Sciences -Steno Diabetes Center A/S -U.S. Department of Veterans Affairs For more information visit http://www.researchandmarkets.com/research/djktj4/diabetic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ChemoCentryx to Present at the 32nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Wed Jan 08, 7:30AM CST
ChemoCentryx, Inc. (Nasdaq:CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 32 Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2014, at 3:30 p.m. Pacific Time. The conference will be held at the Westin St. Francis Hotel in San Francisco, CA.
ChemoCentryx (CCXI) Jumps: Stock Up 5.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 02, 8:39AM CST
ChemoCentryx, Inc. was a big mover last session, as its shares rose almost 6% on the day.
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 16, 7:05AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 23, 2013.
Positive Data on ChemoCentryx Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 05, 9:20AM CST
ChemoCentryx reported positive top-line results from a study on CCX168.
JC Penney and OmniVision are big market movers
AP - Wed Dec 04, 3:58PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:
Keep an Eye on Ligand, Medivation, ChemoCentryx, and Teva Today
Leo Sun, The Motley Fool - Motley Fool - Wed Dec 04, 8:51AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! Let's check in...
Why You Shouldn't Bet Against ChemoCentryx (CCXI) Stock - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:59AM CDT
One stock that might be an intriguing choice for investors right now is ChemoCentryx
Nasdaq stocks posting largest percentage decreases
AP - Thu Apr 10, 12:34PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at 1 p.m.:
ChemoCentryx Appoints Anne-Marie S. Duliege, M.D., M.S. to Chief Strategic Development Role and Head of Immuno-Oncology
GlobeNewswire - Thu Mar 27, 7:30AM CDT
ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, announced today that it has appointed Anne-Marie S. Duliege, M.D., M.S., to a newly created position within the Company. Effective immediately, Dr. Duliege will be acting as Executive Vice President, Chief of Strategic Development and Head of Immuno-oncology.
ChemoCentryx (CCXI) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Mar 20, 7:36AM CDT
ChemoCentryx (CCXI) Shares March Higher, Can It Continue?
ChemoCentryx (CCXI) Jumps: Stock Rises 9.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 7:51AM CDT
ChemoCentryx, Inc. was a big mover last session, as its shares rose nearly 10% on the day.
ChemoCentryx Announces Financial Results for the Quarter and Year Ended December 31, 2013
GlobeNewswire - Thu Mar 13, 3:05PM CDT
ChemoCentryx, Inc., (Nasdaq:CCXI), a clinical-stage biopharmaceutical company focused on autoimmune diseases, inflammatory disorders and cancer, announced today its financial results for the fourth quarter and year ended December 31, 2013.
ChemoCentryx to Hold Fourth Quarter and Year-End 2013 Financial Results Conference Call on Thursday, March 13, 2014
GlobeNewswire - Mon Mar 03, 7:30AM CST
ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that the Company's fourth quarter and year-end 2013 financial results will be released after market close on Thursday, March 13, 2014. ChemoCentryx executive management will host a conference call beginning at 5:00 p.m. Eastern Time on March 13, 2014, to discuss these results and to answer questions.
ChemoCentryx to Present at the Cowen and Company 34th Annual Health Care Conference
GlobeNewswire - Tue Feb 25, 9:28AM CST
ChemoCentryx, Inc. (Nasdaq:CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the Cowen and Company 34 Annual Health Care Conference on Tuesday, March 4, 2014, at 10:40 a.m. Eastern Time at The Boston Marriott Copley Place hotel in Boston, MA.
5 Stocks Poised for Breakouts
at The Street - Fri Feb 21, 12:53PM CST
These stocks look ready to break out and trade higher from current levels.
5 Under-$10 Biotech Stocks to Watch
at The Street - Fri Jan 10, 6:00AM CST
Keep these biotech stocks on your radar.
Diabetic Nephropathy Global Clinical Trials Review, H2 2013 Available Now for Review
M2 - Thu Jan 09, 4:55AM CST
Research and Markets (http://www.researchandmarkets.com/research/djktj4/diabetic) has announced the addition of the "Diabetic Nephropathy Global Clinical Trials Review, H2, 2013" report to their offering. The clinical trial report, Diabetic Nephropathy Global Clinical Trials Review, H2, 2013" provides data on the Diabetic Nephropathy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Diabetic Nephropathy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Diabetic Nephropathy. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Companies Mentioned: -Abbott Laboratories -AbbVie Inc. -Bayer AG -ChemoCentryx, Inc. -Eli Lilly and Company -GenKyoTex S.A. -Holstebro Hospital -IMMD Inc. -Islamic Azad University of Tabriz -Joslin Diabetes Center -Kanazawa Medical University -Novartis AG -Okayama University -Pfizer Inc. -Shanghai Jiao Tong University -Shiraz University of Medical Sciences -Steno Diabetes Center A/S -U.S. Department of Veterans Affairs For more information visit http://www.researchandmarkets.com/research/djktj4/diabetic About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
ChemoCentryx to Present at the 32nd Annual J.P. Morgan Healthcare Conference
GlobeNewswire - Wed Jan 08, 7:30AM CST
ChemoCentryx, Inc. (Nasdaq:CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 32 Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2014, at 3:30 p.m. Pacific Time. The conference will be held at the Westin St. Francis Hotel in San Francisco, CA.
ChemoCentryx (CCXI) Jumps: Stock Up 5.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Jan 02, 8:39AM CST
ChemoCentryx, Inc. was a big mover last session, as its shares rose almost 6% on the day.
Annual Changes to the NASDAQ Biotechnology Index
GlobeNewswire - Mon Dec 16, 7:05AM CST
The NASDAQ OMX Group, Inc. (Nasdaq:NDAQ) today announced the results of the annual re-ranking of the NASDAQ Biotechnology Index (Nasdaq:NBI), which will become effective prior to market open on Monday, December 23, 2013.
Positive Data on ChemoCentryx Candidate - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Dec 05, 9:20AM CST
ChemoCentryx reported positive top-line results from a study on CCX168.
JC Penney and OmniVision are big market movers
AP - Wed Dec 04, 3:58PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:
Keep an Eye on Ligand, Medivation, ChemoCentryx, and Teva Today
Leo Sun, The Motley Fool - Motley Fool - Wed Dec 04, 8:51AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! Let's check in...
